ELI LILLY AND COMPANY Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
ELI LILLY AND COMPANY (LLY) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $33.40 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2025-02-19
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2016-06-30 was $0.00.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2016-03-31 was $140.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2009-09-30 was $190.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $33.40M, a 610.64% increase from fiscal 2023.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $4.70M, a 89.51% decline from fiscal 2022.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $44.80M, a 16.36% increase from fiscal 2021.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2021 was $38.50M, a 46.53% decline from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | $33.40M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $4.70M 10-K · filed 2025-02-19 | |||
| 2022-12-31 | $44.80M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | $38.50M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $72.00M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $260.50M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $33.20M 10-K · filed 2021-02-17 | |||
| 2017-12-31 | $2.40M 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $171.90M 8-K · filed 2019-10-24 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $140.00M 10-Q · filed 2016-07-28 | ||
| 2016-03-31 | $140.00M 10-Q · filed 2017-10-27 | |||
| 2015-12-31 | $446.20M 10-K · filed 2018-02-20 | |||
| 2014-12-31 | $4.20M 10-K · filed 2017-02-21 | |||
| 2013-12-31 | $404.90M 10-K · filed 2016-02-19 | |||
| 2012-12-31 | $9.20M 10-K · filed 2015-02-19 | -$9.20M 10-K · filed 2013-02-21 | ||
| 2011-12-31 | $326.30M 10-K · filed 2014-02-19 | -$326.30M 10-K · filed 2012-02-24 | ||
| 2010-12-31 | -$100.00K 10-K · filed 2013-02-21 | |||
| 2009-12-31 | -$95.00M 10-K · filed 2012-02-24 | -$178.80M 10-K · filed 2011-02-22 | ||
| 2009-09-30 | $190.00M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |